3Raffai R,Vukmirica J,Weisgraber KH,et al.Bacterial expression and purification of the Fab fragment of a monoclonal antibody specific for the low-density lipoprotein receptor-binding site of human apolipoprotein E[J].Protein Expr Purif,1999,16(1):84.
4Sinha AA,Quast BJ,Reddy PK,et al.Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2'-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice[J].Anticancer Res,1999,19(2A):893.
5Muyldermans S,Cambillau C,Wyns L.Recognition of antigens by single-domain antibody fragments:the superfluous luxury of paired domains[J].Trends Biochem Sci,2001,26(4):230.
7Thomas MB,Martin B,Michael G,et al.High-linear energy transfer(LET) versus low-let emitters in radioimmunotherapy of solid tumors:therapeutic efficacy and dose-limiting toxicity of labeled CO17-1Afragments in a human colonic cancer model[J].Cancer Res,1999,59(11):2635.
10Penichet ML,Dela JS,Shin SU,et al.A recombinant Ig3-(IL-2) fusion protein for the treatment of human HERI/neu expressing tumors[J].Hum Antibodies,2001,10(1):43.
3[1]Rosenberg SA,Yang JC,White DE,et al. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2:identification of the antigens mediating response[J].Ann Surg,1998,228(3):307-319.
4[2]Cohen J. IL-12 deaths:explanation and a puzzle[J].Science,1995,270(5238):908.
5[3]Mass RA,Dullens HF,De Jong WH,et al. Immunotherapy of mice with a larg burden of disseminated lymphoma with low-dose interleukin-2[J].Cancer Res,1989,49(24):7037-7040.
6[4]Soiffer R,Lynch T,Mihm M,et al. Vaccination with irradiated aut-ologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma[J].Pro Natl Acad Sci USA,1998,95(22):13141-13146.
7[5]Hrouda D,Perry M,Dalagleish A G. Gene therapy for prostate cancer[J].Semin Oncol,1999,26(4):455-471.
8[6]Grimm EA,Mazumder A,Zhang HZ,et al. Lymphokine-activated kille cell phenomenon.Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes[J].J Exp Med,1982,155(6):1823-1841.
10[8]Harvill ET,Fleming JM,Morrison SL. An IgG3-IL-2 fusion protein has higher affinity than hrIL-2 for the IL-2R alpha subunit:real time measurement of ligand binding[J].Mol Immunol,1996,33(12):1007-1014.
